Arthur Donohue-Rolfe

Arthur Donohue-Rolfe
Associate Professor Emeritus
Associate Professor Emeritus
Infectious Disease, Microbial Pathogenesis

Campus Phone:
508-839-7919

Fax:
508-839-8787

Education

  • PhD - Tufts University - 1979
  • BS - Haverford College - 1971
  1. Mallick, E.M., Brady, M.J., Luperchio, S.A., Vanguri, V.K., Magoun, L., Liu, H., Sheppard, B.J., Mukherjee, J., Donohue-Rolfe, A., Tzipori, S., Leong, J.M., Schauer, D.B. 2012. Allele- and Tir-independent functions of intimin in diverse animal infection models. Frontiers in Microbiology.
  2. Kuntumalla, S., Zhang, Q., Braisted, J.C., Fleischmann, R.D., Peterson, S.N., Donohue-Rolfe, A., Tzipori, S., Pieper, R. 2011. In vivo versus in vitro protein abundance analysis of Shigella dysenteriae type 1 reveals changes in the expression of proteins involved in virulence, stress and energy metabolism. BMC Microbiology.
  3. Brady, M.J., Radhakrishnan, P., Liu, H., Magoun, L., Murphy, K.C., Mukherjee, J., Donohue-Rolfe, A., Tzipori, S., Leong, J.M. 2011. Enhanced actin pedestal formation by enterohemorrhagic Escherichia coli O157:H7 adapted to the mammalian host. Frontiers in Microbiology.
  4. Pieper, R., Zhang, Q., Parmar, P.P., Huang, S.-T., Clark, D.J., Alami, H., Donohue-Rolfe, A., Fleischmann, R.D., Peterson, S.N., Tzipori, S. 2009. The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins. Proteomics.
  5. Kuntumalla, S., Braisted, J.C., Huang, S.-T., Parmar, P.P., Clark, D.J., Alami, H., Zhang, Q., Donohue-Rolfe, A., Tzipori, S., Fleischmann, R.D., Peterson, S.N., Pieper, R. 2009. Comparison of two label-free global quantitation methods, APEX and 2D gel electrophoresis, applied to the Shigella dysenteriae proteome. Proteome Science.
  6. Zhang, Q., Donohue-Rolfe, A., Krautz-Peterson, G., Sevo, M., Parry, N., Abeijon, C., Tzipori, S. 2009. Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. Journal of Infectious Diseases.
  7. Ritchie, J.M., Brady, M.J., Riley, K.N., Ho, T.D., Campellone, K.G., Herman, I.M., Donohue-Rolfe, A., Tzipori, S., Waldor, M.K., Leong, J.M. 2008. EspF U, a type III-translocated effector of actin assembly, fosters epithelial association and late-stage intestinal colonization by E. coli O157:H7. Cellular Microbiology.
  8. Campellone, K.G., Roe, A.J., Løbner-Olesen, A., Murphy, K.C., Magoun, L., Brady, M.J., Donohue-Rolfe, A., Tzipori, S., Gally, D.L., Leong, J.M., Marinus, M.G. 2007. Increased adherence and actin pedestal formation by dam-deficient enterohaemorrhagic Escherichia coli O157:H7. Molecular Microbiology.
  9. Sheoran, A.S., Chapman-Bonofiglio, S., Harvey, B.R., Mukherjee, J., Georgiou, G., Donohue-Rolfe, A., Tzipori, S. 2005. Human antibody against Shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infection and Immunity.
  10. Akiyoshi, D.E., Rich, C.M., O'Sullivan-Murphy, S., Richard, L., Dilo, J., Donohue-Rolfe, A., Sheoran, A.S., Chapman-Bonofiglio, S., Tzipori, S. 2005. Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells. Infection and Immunity.
  11. Tzipori, S., Sheoran, A., Akiyoshi, D., Donohue-Rolfe, A., Trachtman, H. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clinical Microbiology Reviews.
  12. Sheoran, A.S., Chapman, S., Singh, P., Donohue-Rolfe, A., Tzipori, S. 2003. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infection and Immunity.
  13. Mukherjee, J., Chios, K., Fishwild, D., Hudson, D., O'Donnell, S., Rich, S.M., Donohue-Rolfe, A., Tzipori, S. 2002. Production and characterization of protective human antibodies against Shiga toxin 1. Infection and Immunity.
  14. Mukherjee, J., Chios, K., Fishwild, D., Hudson, D., O'Donnell, S., Rich, S.M., Donohue-Rolfe, A., Tzipori, S. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infection and Immunity.
  15. Thompson, G.S., Shimizu, H., Homans, S.W., Donohue-Rolfe, A. 2000. Localization of the binding site for the oligosaccharide moiety of Gb3 on verotoxin 1 using NMR residual dipolar coupling measurements. Biochemistry.
  16. Donohue-Rolfe, A., Kondova, I., Oswald, S., Hutto, D., Tzipori, S. 2000. Escherichia coli 0157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2. Journal of Infectious Diseases.
  17. Konadu, E., Donohue-Rolfe, A., Calderwood, S.B., Pozsgay, V., Shiloach, J., Robbins, J.B., Szu, S.C. 1999. Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. Infection and Immunity.
  18. Donohue-Rolfe, A., Kondova, I., Mukherjee, J., Chios, K., Hutto, D., Tzipori, S. 1999. Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. Infection and Immunity.
  19. Shimizu, H., Donohue-Rolfe, A., Homans, S.W. 1999. Derivation of the bound-state conformation of a ligand in a weakly aligned ligand - Protein complex. Journal of the American Chemical Society.
  20. Fuchs, S., Mühldorfer, I., Donohue-Rolfe, A., Kerényi, M., Emödy, L., Alexiev, R., Nenkov, P., Hacker, J. 1999. Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microbial Pathogenesis.

General Research Interests

My general research interest is the pathogenesis of enteric bacterial pathogens. My particular current interest is understanding the pathogenesis of enterohemorrhagic E. coli (EHEC). EHEC produces two toxins, Shiga toxin 1 and Shiga toxin 2. My laboratory has studied the basic structure of these toxins and is continuing to study their role in disease and the effects of immune therapy directed against the toxins may have in ameliorating the disease.

Selected Research Projects

  • Antibiotic treatment of EHEC infections. The treatment with antibiotics of human patients infected with EHEC is controversial. Studies have shown that treatment with some antibiotics may, in fact, worsen the clinical outcome. This study investigates the mechanisms by which certain antibiotics lead to a more severe illness. Selection of antibiotics which actually improve the clinical outcome will be a goal of this project.
  • Shiga toxin 2 and its association with hemolytic uremic syndrome (HUS) HUS development is a systemic complication of EHEC infections and is strongly associated with EHEC strains that produce just Shiga toxin 2. HUS produces not only temporary kidney malfunctioning but can also lead to permanent kidney malfunctioning and even death. We are studying why Shiga toxin 2 is more associated with HUS development than Shiga toxin 1.

Research and Clinical Interests

  • The pathogenesis of bacteria
  • The pathogenic E. coli
  • The diagnosis of infectious diseases

Research Interests by Area

Infectious Diseases: Pathogenesis/Host Response
  • E. Coli O157 toxins
Infectious Diseases: Prevention and Control
  • Antibiotic treatment of EHEC infections

Major Specialized Equipment

  • ELISA plate reader
  • Electroporator